Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

PURPOSE: To compare the visual and anatomic outcomes of aflibercept versus ranibizumab as a second line treatment for persistent diabetic macular edema (DME) after initial bevacizumab injections. METHODS: In this retrospective cohort study, patients with center-involved DME of ≥ 300 μm thickness aft...

詳細記述

保存先:
書誌詳細
出版年:Clin Ophthalmol
主要な著者: Alsaedi, Nasser G, Alselaimy, Ruba M, Alshamrani, Abdulaziz A, AlAjmi, Muhammed, Khandekar, Rajiv, Al-Dhibi, Hassan, Al-Abdullah, Abdulelah A
フォーマット: Artigo
言語:Inglês
出版事項: Dove 2021
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8286127/
https://ncbi.nlm.nih.gov/pubmed/34285463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S316271
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料